Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

Inclusion Criteria

• Diagnosed with Stage IV metastatic melanoma, or inoperable Stage III equivalent
• Baseline fluorodeoxyglucose (FDG)-PET scan available from within 30 days prior to date of enrollment
• Blood counts and metabolic results within protocol limits within 14 days prior to enrollment
• Ability to lie flat and still for a minimum of two hours for imaging
• Male and female participants with reproductive potential must agree to use highly effective contraception in preparation of the study, during the study, and for 4 weeks following the last dose of an investigative imaging agent
• Documented life expectancy of at least 3 months

Exclusion Criteria

• Active secondary malignancy
• Prior treatment (for any reason) with radioactive nuclides; imaging tracers are acceptable
• Pregnancy or breast feeding a child
• Uncontrolled infection
• Treatment with another investigational drug within 30 days prior to enrollment date
• Any treatment with BRAF inhibitors since the baseline FDG-PET scan or plans for such treatment during the study
• Kidney function not within protocol limits
• BMI>40 kg/m2
• History of a condition resulting in anaphylaxis or angioedema